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Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterised by 
behavioural and social impairments. ASD shows evidence of a genetic aetiology, with a large 
body of research linking ASD to polymorphisms in several different genes and gene families, 
including those involved in circadian rhythm generation and melatonin biosynthesis. Sleep 
disorders are highly comorbid with ASD in both children and adults, and range from sleep 
onset delay, phase shift and sleep disruption. These parasomnias can have a significant 
impact on the quality of life for persons with ASD and their families, and sleep deprivation 
can feed into the behavioural deficits in ASD. Melatonin supplementation is often 
prescribed to assist in alleviating the above mentioned sleep dysfunction. Melatonin is a 
hormone in the circadian clock system, and is a biochemical signal for darkness to 
synchronise peripheral cells to the master oscillator. Clinical trials reported that melatonin 
supplementation at night assists in sleep initiation. However both the mode of action of 
supplemental melatonin, as well as whether melatonin deficiency is common in ASD, 
remains unclear. Furthermore, any research on ASD is often hamstrung by the 
heterogeneous nature of the disorder, necessitating clear phenotyping. This study examines 
single nucleotide polymorphisms (SNPs) in the gene acetylserotonin methyl transferase 
(ASMT), which encodes an enzyme in melatonin biosynthesis, in a South African ASD cohort 
(n=28) and controls (n=6). All participants completed and Autism Diagnostic Observation 
Schedule-2 assessment that allowed partitioning of the ASD individuals into ASD 
endophenotypes, to reduce phenotyping heterogeneity. This study found SNPs previously 
associated with ASD in the promoter and intronic region. Additionally, this study found 
novel SNPs, and a SNP in a putative transcription factor binding site not previously 
associated with ASD. The associations found between SNPs and ASD endophenotypes, 
together with the positions of the SNPs, suggest a potential link between ASMT 
polymorphisms and ASD symptom severity. Further research, using language assessment 
tools as well as quantitative measures of melatonin and sleep disruption, may establish the 
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1.1  AUTISM SPECTRUM DISORDERS 
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterised by 
behavioural and social impairments. The fifth edition of the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-5) consolidated the diagnoses of Asperger’s Disorder, 
Pervasive Developmental Disorder, and Autism Disorder into Autism Spectrum Disorders 
(ASD) (American Psychiatric Association 2013). These disorders represent a sliding scale of 
impairments from mild to severe symptoms, including limitations in social communication, 
problems in interpersonal interaction, repetitive behaviours and restricted interests. ASD is 
frequently associated with behavioural comorbidities, such as anxiety or depressive 
disorders, as well as medical comorbidities including epilepsy and sleep disruption (Jonsson 
et al. 2010; Hu & Steinberg 2009, American Psychiatric Association 2013). ASD exhibits 
strong heritability, and is a life-long condition. The median prevalence is estimated to be 65 
in every 10,000 people worldwide (Elsabbagh et al. 2012; Jonsson et al. 2010). 
ASD manifests with an extremely heterogeneous symptom set; symptom severity ranges 
from mild to severe or debilitating. The DSM-4 diagnosis of Asperger’s disorder represented 
the milder end of the spectrum, characterised by relatively average to above-average IQ and 
verbal fluency, yet still exhibiting intrinsic difficulty with interpersonal interaction (Hu & 
Steinberg 2009, American Psychiatric Association 2000). While such individuals can function 
independently and effectively in society, others with more severe impairments or 
comorbidities may remain largely dependent on parents or care-givers (Elsabbagh et al. 
2012). Severely affected individuals may present with symptoms including cognitive 
impairment, compulsions, restricted verbal fluency, sensory aversions or savant skills (Hu et 
al. 2009; Jonsson et al. 2010; Courchesne et al. 2007). 
ASD manifests in early childhood, and the first symptoms (such as delays in developmental 
milestones) appearing between one and two years of age (Courchesne et al. 2007). Some 
children may only show ASD symptoms after a period of typical development, sometimes 
losing previously acquired verbal or non-verbal communicative skills. This phenomenon is 
known as autistic regression, and occurs in approximately one in every three ASD cases (see 
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Giannotti et al (2008) and sources within). Clinical diagnosis of ASD or Pervasive 
Developmental Disorder- Not Otherwise Specified (PDD-NOS), the mildest phenotype in ASD 
(American Psychiatric Association 2000), is usually made between the age of one to four 
years of age (Courchesne et al. 2007; Szatmari et al. 2015). Currently, there is no 
quantitative medical test for ASD and diagnosis is made using standardised psychological 
diagnostic tools such as the Autism Diagnostic Observation Schedule-2 (ADOS-2) together 
with developmental history questionnaires such as the Autism Diagnostic Interview – 
Revised (ADI-R) (Lord et al. 1994; Lord et al. 1989). 
While genetic tests for autism have not been developed yet, ASD shows strong evidence of a 
genetic aetiology, with a large body of research linking ASD to polymorphisms in several 
different genes and gene families (Glessner et al. 2009; Arieff et al. 2010; Bartlett et al. 
2005; Jonsson et al. 2014; Nicholas et al. 2007; Pinto et al. 2010). However, genetic studies 
are hamstrung by the variable nature of the behaviours of the autism spectrum, making it 
extremely difficult to identify target genes from such a heterogeneous phenotype. Due to 
the variable nature of ASD it is essential to consider “subtypes” or endophenotypes of 
autism when looking at the disorder at a molecular level. A good example of this approach is 
the study by Hu et al. (2009) which used microarrays to examine thousands of genes for 
differential expression. This study divided phenotypic variants of ASD into three groups, to 
compare the gene expression of these groups to one another and to age-matched controls. 
An unprecedented result of this study was the differences in gene expression that were 
observed both among the three groups of ASD participants and between the ASD group and 
the controls. This study emphasises the importance of clear phenotyping in molecular 
research, which includes sequencing studies examining single nucleotide polymorphisms 
(SNPs). In order to reduce the heterogeneity in a sample group, past studies would identify a 
particular trait, for example sleep disruption, or the degree of age-appropriate language 
acquisition in participants (Hu et al. 2009) (Veatch, Pendergast, et al. 2015; Jonsson et al. 
2010; Melke et al. 2008).  
6 
 
1.2  CIRCADIAN CYCLES AND THE ROLE OF MELATONIN 
Molecular studies on neuropsychiatric disorders, including ASD, have implicated a variety of 
regulatory or responsive genes that form part of the human circadian clock system (Hu et al. 
2009; Talarowska et al. 2014; Gałecki et al. 2010; Etain et al. 2012; Geoffroy et al. 2015; Li et 
al. 2012). Circadian rhythms are generated by an organism’s internal clock, which regulates 
many physiological processes such as immunity, metabolism and sleep patterns. Differential 
expression of circadian genes has also been associated with endophenotypes within ASD. In 
a previous study, Hu et al (2009) subdivided their ASD cohort into three different groups 
(“savant”, “severe language impairment” and “mild ASD”), and compared the gene 
expression among these groups, and to controls. They found that 15 circadian genes were 
differentially expressed specifically in the group with severe language impairment, and not 
in the other two ASD groups, when compared to the control group (Hu et al. 2009). This 
highlights not only the importance of endophenotyping in ASD studies, but also that 
circadian genes may be implicated in language development or symptom severity in ASD. 
Circadian cycles also regulate behavioural processes such as social timing, for example 
interactive turn-taking in conversation, or rapid shifts in attention (Wimpory et al. 2002). It 
has been proposed that such timing difficulties may be central to ASD, potentially even 
playing a causative role (Nicholas et al. 2007; Wimpory et al. 2002). However, the 
mechanism by which circadian disruption directly influences the development of ASD has 
not been elucidated. 
In mammals, the circadian system is directed by the master oscillator, situated in the 
superchiasmatic nucleus (SCN) of the hypothalamus (Figure 1.1). This is the main biological 
clock and synchronises the clock system present in each cell (Jin et al. 1999). The biological 
clock is a core group of genes that form a system of transcription and translation feedback 
loops, creating an internal biochemical and electric cycle with a period of around 24 hours 
(Czeisler et al. 1999; Ko & Takahashi 2006). While these cycles are endogenous and self-
sustaining, they can be influenced by environmental factors known as zeitgebers, such as 
light, sound or social cues (Wimpory et al. 2002; Wittmann et al. 2006; Roenneberg et al. 
2003). The master oscillator is synchronised to the night/day cycle of the earth’s cycle 




Figure 1.1 Circadian Cycle and Regulation of Melatonin: In mammals, the SCN houses the master 
oscillator, which governs all other oscillators in the body. The oscillator is comprised of several 
transcription/translation feedback loops that generate rhythmicity. This master oscillator is 
independent and self-sustaining, but can be reset by light. Light signals detected by the retinal 
ganglia of the eye cause a signal to be transduced to the SCN via the retinohypothalamic tract, 
indicated by arrows. The SCN signals the paraventricular nucleus, which stimulates the pineal gland. 
In the absence of light, melatonin is synthesised in the pineal gland. Melatonin thus acts as a signal 
for darkness for oscillators in the rest of the body, as well as on the SCN itself. Image of 
transcription/translation feedback loop taken from Ko & Takahashi (2006). 
Light signals are detected by the rod and cone cells in the eye, as well as the retinal ganglia. 
These structures transduce the light signal to the SCN via the retinohypothalamic tract (see 
Figure 1.1). The SCN stimulates a further neurological signalling cascade, which ultimately 
stimulates the pineal gland through the paraventricular nucleus (Ko & Takahashi 2006). In 
the pineal gland, the melatonin biosynthetic pathway starts with the dietary amino acid L-
tryptophan, which is converted to the hormone serotonin in two enzymatic steps (Figure 
1.2). Only in the absence of light, the enzyme aryl-alkylamine N-acetyltransferase (A-ANAT) 
is transcribed and activated. This enzyme acetylases serotonin to N-acetylserotonin. The 
final enzyme, acetyl serotonin methyl transferase (ASMT), converts N-acetylserotonin into 
melatonin (Chaste et al. 2010; Macchi & Bruce 2004; Ko & Takahashi 2006). Because the 
expression of A-ANAT only occurs in darkness, melatonin acts as a biochemical cue for 
darkness from the central oscillator to oscillators in peripheral tissues (Macchi & Bruce 
2004). Once melatonin has been synthesised, it is secreted into the bloodstream, and then 
passes to the cerebrospinal fluid through the choroid plexus (Pandi-Perumal et al. 2008). 
Melatonin is ultimately broken down by the enzyme cytochrome P450 1A2 (CYP1A2) in the 




Figure 1.2 The melatonin biosynthetic pathway: The dietary amino acid L-tryptophan is taken up 
into the pineal gland. Here it is converted to another amino acid, 5-hydroxytryptophan, by the 
enzyme tryptophan 5-hydroxylase. The hormone serotonin is synthesised from 5-hydroxytryptophan 
through the action of the enzyme aromatic L-amino acid decarboxylase. With the onset of darkness, 
the enzyme aryl-alkylamine N-acetyltransferase (A-ANAT) is transcribed and activated in the pineal 
gland, where it acetylises serotonin. The product of this enzyme, N-acetylserotonin, is converted to 
melatonin by the enzyme acetylserotonin methyl transferase (ASMT) (Macchi & Bruce 2004). 
 
Several studies have found associations between melatonin pathway polymorphisms and 
ASD (Jonsson et al. 2014; Melke et al. 2008; Toma et al. 2007). As melatonin is the hormone 
that synchronises the clock system in peripheral tissue to the main oscillator in the SCN, it 
has been suggested that melatonin may play a role in circadian disruption in ASD (Veatch, 
Pendergast, et al. 2015; Pagan et al. 2014). In addition to genetic polymorphisms and 
differential regulation, some studies have also found decreased melatonin levels, or 
decreased ASMT transcript levels (Melke et al. 2008; Hu et al. 2009; Malow et al. 2006; 
Goldman et al. 2014). 
The role of melatonin in the sleep cycle, and sleep disruption, is well-characterised 
(Hardeland 2012). It is important, however, to note that sleep disruption or circadian 
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rhythm sleep disorders can take on several different forms, with different molecular 
underpinnings (Pandi-Perumal et al. 2008). Exogenous factors can influence melatonin 
secretion and timing, without any intrinsic polymorphism existing in the melatonin pathway 
or circadian clock. The timing or spectrum of light can induce melatonin suppression in a 
way that desynchronises melatonin expression with the natural light-dark cycle. This is often 
the case in shift work or jet lag, but can also be the effect of artificial light from electronic 
devices such as mobile phones or computer screens (Kojo et al. 2005; Wittmann et al. 2006; 
Cajochen et al. 2011). These factors can result in a delay in sleep onset. If this delay is 
chronic, it is referred to as Delayed Sleep Phase Syndrome (DSPS). Individuals with delayed 
sleep onset generally have normal sleep patterns and sleep quality, barring the inability to 
fall asleep at the desired time (Pandi-Perumal et al. 2008). This kind of sleep disruption can 
result from intrinsic factors, such as light sensitivity, or delayed melatonin secretion patterns 
in conjunction with other circadian disruptions (Shibui et al. 2003). Similarly, Advanced 
Sleep Phase Syndrome (ASPS) is characterised by persistent early sleep onset, as well as 
early awakenings. Individuals with this disorder also have a decrease in sleep quality. ASPS 
has been found to be associated with age-related earlier melatonin synthesis, as well as 
familial polymorphisms in clock genes such as Per2 (Pandi-Perumal et al. 2008). 
Melatonin deficiency sometimes occurs in blind individuals, and results in a free-running 
sleep cycle, where the main oscillator is non-synchronised to the natural light/dark cycle. 
However, in some individuals, melatonin deficiency results in non-24 hour sleep cycles, 
rather than advances or delays in sleep cycle (Hardeland 2012). The most obvious cause for 
melatonin deficiency would be disruption in the translation or activation of ASMT and A-
ANAT, or deficiency in tryptophan or serotonin (Hardeland 2012). Polymorphisms in the two 
melatonin receptors may also disrupt melatonin signalling (Pandi-Perumal et al. 2008). 
1.3  SLEEP DISRUPTION IN AUTISM SPECTRUM DISORDERS 
Sleep disorders are very common in individuals with ASD (Veatch, Goldman, et al. 2015) and 
range from sleep onset delay, phase shift and sleep disruption (Malow et al. 2006). These 
parasomnias can have a significant impact on the quality of life of individuals with ASD and 
their families, and sleep deprivation exacerbates the behavioural deficits of ASD (Malow et 
al. 2006; Veatch, Goldman, et al. 2015). To alleviate these parasomnias, health practitioners 
10 
 
often prescribe melatonin supplementation to individuals with ASD. Studies on adults with 
endogenous sleep disruption, without psychiatric, social or developmental disorders, found 
that some individuals may benefit from exogenous melatonin administered at night 
(Brzezinski et al. 2005). Likewise, smaller studies have concluded that it’s possible to entrain 
the sleep cycle of blind people with free-running sleep phase (Pandi-Perumal et al. 2008; 
Hardeland 2012). A meta-analysis of melatonin therapy on adults with sleep disorders that 
accompany shift work or jet lag, concluded that melatonin supplementation was not 
effective in these cases (Buscemi et al. 2006). Some studies have shown that individuals 
with ASD who experience sleep disruption benefit from receiving melatonin supplements at 
night, particularly in inducing sleep onset, with less effect in early or nocturnal waking (Jan 
& Freeman 2004; Rossignol & Frye 2011; Malow et al. 2012; Wright et al. 2011). A trial 
examining a cohort of children with neurodevelopmental disorders, including some children 
with autism, concluded that melatonin supplementation did not improve sleep efficiency, or 
early waking (Gringras et al. 2012). This finding is consistent with the role of melatonin in 
the circadian system, as previously discussed. A potential confounding factor when 
comparing results among these studies, and within the meta-analyses, is that there is little 
standardisation in the dose prescribed, the time of administration, or the form in which the 
melatonin was administered. It is also not stated what, if any, environmental factors such as 
nocturnal light or consistent bed-time were addressed, or whether the study participants 
had a melatonin deficiency. 
A point to consider, however, is that melatonin is involved in several cellular processes in 
addition to its role in the sleep cycle (Hardeland et al. 2011). A study by Veatch et al (2015) 
found that even in ASD children with endogenous melatonin levels comparable to that of 
typically-developing children, responded to melatonin supplementation, and fell asleep 
faster. Based on this finding, they suggested that melatonin may have additional effects, not 
limited to its action as a chronobiotic, such as anxiolytic, hypnotic or sedative effects 




1.4  ACETYLSEROTONIN METHYL TRANSFERASE: A CANDIDATE GENE IN AUTISM 
Given that A-ANAT is the rate-limiting enzyme in melatonin synthesis, it was a logical 
putative gene in autism circadian research. However, results from A-ANAT studies have not 
concretely established this gene as a key component of ASD aetiology (Hu et al. 2009; Hu & 
Steinberg 2009). Furthermore, Melke et al (2008) reported elevated levels of n-
acetylserotonin in conjunction with low levels of melatonin in individuals with ASD. Because 
n-acetylserotonin is the product of the action of A-ANAT, this indicates that the A-ANAT 
enzyme is functional. Therefore the levels of n-acetylserotonin in conjunction with  low 
melatonin levels suggests that the melatonin deficiency in ASD could be the result of low 
enzymatic activity of ASMT (Melke et al. 2008; Cotton & Richdale 2010). Previous studies 
examining genetic variation of the ASMT gene found associations of polymorphisms with a 
myriad of psychiatric and circadian disturbances. These disorders include allelic imbalance, 
circadian disruption, acute myocardial infarction, intellectual impairment, Bipolar Mood 
Disorder, Major Depressive Disorder, and ASD (Jonsson et al. 2014; Wang et al. 2013; Melke 
et al. 2008; Etain et al. 2012; Pagan et al. 2011; Pagan et al. 2014; Pereira et al. 2013; Toma 
et al. 2007). 
The ASMT gene is one of the 12 genes affected by deletions in the protease-activated 
receptor (PAR1) in ASD (Melke et al. 2008). Several single-nucleotide polymorphisms (SNPs) 
and splice site mutations in ASMT have been observed in both autism participants and 
participants with clinical depression (Gałecki et al. 2010; Etain et al. 2012). The ASMT gene is 
located on the pseudoautosomal region of the X and Y chromosomes GrCh38.p2 position 
1595455-1643081 (NCBI). The gene is approximately 35kb in length, with several introns 
and exons (NCBI). In humans, the ASMT gene can be alternatively spliced to produce three 
different isoforms, all of which are involved in melatonin biosynthesis (NCBI). 
1.5  MOLECULAR STUDY DESIGN 
When integrating past studies on the ASMT gene (Jonsson et al. 2014; Wang et al. 2013; 
Melke et al. 2008; Pagan et al. 2014; Pereira et al. 2013; Toma et al. 2007), the 
polymorphisms associated with ASD clustered in a few regions of the gene. This study 
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focussed on two of these “cluster” regions: the region spanning from GRCh38.p2 position 
X:1614846-1615299; and the region spanning GRCh38.p2 position X:1629573-1630120.  
The first region, X:1614846-1615299, contains the promoter and 5’-untranslated region 
(UTR) of the ASMT gene. Previous studies have identified an ASD “risk” haplotype in this 
region (Melke et al. 2008; Botros et al. 2013), which consists of the SNPs rs4446909, 
rs5989681, and rs6644635. However, other studies did not significantly implicate this 
haplotype in ASD aetiology (Toma et al. 2007; Wang et al. 2013; Veatch, Pendergast, et al. 
2015). It is noteworthy that many of these studies do not examine specific traits within the 
ASD phenotype, for example sleep disruption (Veatch, Pendergast, et al. 2015), which could 
mean that the data is too heterogeneous to highlight specific genes or polymorphisms. 
Furthermore, it is possible that regional genetic variants within these cohorts confound 
comparison between the international cohorts. We selected this region to investigate the 
presence of the above mentioned risk haplotype, as well as whether regional genetic 
variants were present in a South African population. The second region spans the GrCh38.p2 
position X: 1629573-1630120. This covers exon 5 of ASMT, and part of the intronic region on 
both the 5’ and 3’ end of exon 5. This region has not been as well-studied as the promoter 
region, but SNPs in this region were associated ASD (Wang et al. 2013; Pereira et al. 2013; 
Holt et al. 2010) 
1.6  ASD ENDOPHENOTYPING 
In addition to the published clinical uses of ADOS (Autism Diagnostic Observation Schedule) 
assessments as a diagnostic tool, this study used ADOS assessment criteria as a phenotyping 
tool. The ADOS tool assigns numerical scores to behaviours observed during the assessment, 
in both structured and unstructured play. The behaviours are divided into three broad 
categories: Communication (for example, reporting of events, and use of gestures), 
Reciprocal Social Interaction (for example, eye contact and forming a rapport with the 
assessor), and Restrictive and Repetitive Behaviours (for example, stereotyped use of 
language, or stereotyped and repetitive movements). The sum of these scores (the Overall 
Total) is interpreted using different cut-offs, based on the age and verbal fluency of the 
individual (see Table 1.1), to establish the ADOS diagnosis/classification. Symptom Severity 
is established by assigning a Comparison Score, which ranges from 1 to 10, based on the 
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Overall Total Score, the chronological age of the participant, and the Module number with 
which they were assessed. A Comparison Score of 1-2 represents Minimal-to-No Evidence of 
spectrum-related symptoms, 3-4 represents a Low level of symptoms, 5-7 represents a 
Moderate level of symptoms, and 8-10 represents a High symptom severity. 
1.7 THE PRESENT STUDY 
This study will examine the genotypes of children with ASD, at the two genetic regions 
described in Section 1.5. The genotypes of the ASD cohort will be compared to that of 
typically developing age-matched controls. The goal is to establish if children on the Autism 
spectrum have any significant genetic changes or variants compared to typically developing 
children. The study will also sub-group the ASD cohort to look for genetic variability within 
the ASD group. 
Table 1.1 Table indicating the cut-off scores for diagnosis/classification of ASD using the ADOS 
assessment, taking into account the verbal fluency and age-appropriate linguistic development of 
the individual. 
ADOS Module ADOS Classification Developmental Marker Overall Total Score 
Module 1 
Autism 
Few to no words 16 or higher 
Some words 12 or higher 
Autism Spectrum 
Few to no words 11 to 15 
Some words 8 to 11 
Non-Spectrum 
Few to no words 10 or lower 
Some words 7 or lower 
Module 2 
Autism 
Younger than 5 years 10 or higher 
Age 5 or older 
Simple phase speech 
9 or higher 
Autism Spectrum 
Younger than 5 years 7 to 9 
Age 5 or older 
Simple phase speech 
Equal to 8 
Non-Spectrum 
Younger than 5 years 6 or lower 
Age 5 or older 
Simple phase speech 
7 or lower 
Module 3 
Autism Fluent Speech 9 or higher 
Autism Spectrum Fluent Speech  7 or 8 




2  MATERIALS AND METHODS 
2.1 ETHICS CLEARANCE 
Ethics clearance was granted by the University of Cape Town, Faculty of Science Research 
Ethics Committee, FSREC 076-2014. Approval to approach schools was granted by Western 
Cape Research Services, 20141002-37506. 
2.2 RESEARCH PARTICIPANTS 
Children with ASD were recruited from two schools for children with developmental or 
social disabilities, while typically developing children (controls) were recruited from 
mainstream primary schools and sports clubs in Cape Town, South Africa. After informed 
parental consent (sample of consent form Supplementary Figure 6.1), children were 
recruited to participate in in the study. This study forms part of a larger ASD genomic and 
epigenetic research programme, so the cohort is of a specific age range with age-matched 
controls. Participants were aged from 5 to 14 years old and were unrelated males from 
African (BA), European (WA) and Mixed ancestry (MA). All participants, including controls, 
were screened using the Autism Diagnostic Observation Schedule-2 (ADOS-2) (Lord et al. 
1989) by certified, research reliable ADOS administrators.  
Participants in the ASD group were required to have a prior diagnosis of ASD, as the ADOS 
assessments in this study were used for categorisation and phenotyping, not as part of a 
clinical diagnosis. Participants with known chromosomal disorders, such as 
Neurofibromatosis or Fragile X syndrome were excluded from the final data set. Typically 
developing children were only considered if they had no social or learning disability 
diagnoses, and were excluded from the final data set if they scored above zero on the ADOS 
final algorithm. The study recruited 50 children with previous diagnoses of ASD and 7 
typically developing children as controls. Of the recruited children with ASD, 32 participants 
allowed DNA to be sampled using buccal swabs (see Table 2.1). Due to the exclusion criteria, 
the Final Study Sample consisted of 28 children with ASDs, and 6 controls; all with a 
stringent, “clean” phenotype. After informed parental consent had been obtained in writing, 
the research participants were assessed using the ADOS-2, and if they met the study criteria, 
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a genetic sample was obtained using buccal swabs. Noteworthy is that this study is part of a 
programme that is building an ASD cohort de novo, hence the limited sample size. 
Table 2.1 Table indicating the selection criteria for the cohort used in this study, as well as the 
demographic breakdown of each phenotype, and the number of participants in each subgroup. 
BA= Black ancestry; MA= Mixed ancestry; WA= White ancestry 
 
2.3  SAMPLES AND NUCLEIC ACID EXTRACTION 
Buccal swabs were selected for this study because they are non-invasive and do not carry 
the same health risks as working with blood. Is has also been proposed that buccal cells are 
a better proxy for brain tissue than blood, given their developmental lineage, and that blood 
is a mixed cell population (Smith et al. 2015). There is also evidence that melatonin is 
produced in human salivary glands (Shimozuma et al. 2011). 
Buccal cells were obtained using Isohelix DNA swabs (Cell Projects Ltd., Kent, UK). The swabs 
were introduced into the mouths of the participants, and rubbed in a firm circular motion 
on each inner cheek for at least 30 seconds per cheek. Thereafter the swabs were placed in 
lysis buffer (Ethylenediaminetetraacetic acid (EDTA), pH 8; 10 % (w/v) sodium dodecyl 
sulphate (SDS)) at 4°C, for up to a maximum of two weeks before extraction. The genomic 
DNA extraction method was based on a published protocol, but with some modifications 
(Aljanabi & Martinez 1997). In short, the swabs were allowed to return to room 
temperature, for at least one hour prior to incubation, with the addition of 10 mg ml-1 
proteinase K (Thermo Scientific) for 1.5 hours. This was followed by the addition of 
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saturated (6M) NaCl to precipitate cell debris, and centrifuged at 12000 xg for 10 minutes. 
The resulting supernatant was aspirated off, and added to pure isopropanol, and kept at -
8°C overnight. The DNA was pelleted by a further two centrifugation and ethanol wash 
steps. The extracted genomic DNA is stored at -20°C. The DNA was quantified using a 
Nanodrop ND- 1000 spectrophotometer (ThermoScientific). 
2.4 POLYMERASE CHAIN REACTION 
PCR of GRCh38.p2 position X:1614846-1615299 
Each participant was genotyped for SNPs or other polymorphisms in two ASMT gene 
regions, namely the upstream promoter region, and the exon/intron splice junction at 
NC_000023.11 (16300kbp). 
A 454 bp fragment of the promoter region for ASMT was amplified using ThermoScientific 
Phusion High-Fidelity DNA Polymerase (#F-530S) using the forward primer 5'-
ACCTGCTCAATCCATAAGACGA-3' and the reverse primer 5'-ATTCCCCCTTGTCCCACAGA-3' 
designed in this study using Primer BLAST and OligoAnalyzer. PCR reagent concentrations 
and cycling conditions as per Supplementary Table 6.1 and Supplementary Table 6.2. This 
region contains the SNPs rs4446909, rs5989681, rs56690322, rs6644635, and rs17149149, 
previously associated with ASD (Melke et al. 2008; Wang et al. 2013; Toma et al. 2007; 
Veatch, Pendergast, et al. 2015). The success of the PCR, and the PCR product size, was 
confirmed by electrophoresing the PCR product on a 1.2 % (w/v) agarose gel in 1 X tris-
acetate with EDTA (TAE) buffer stained with ethidium bromide. 
PCR of GRCh38.p2 position X:1629573-1630120 
A 548 bp fragment of the exon/intron boundary region for ASMT was amplified using 
ThermoScientific Phusion High-Fidelity DNA Polymerase (#F-530S) using the forward primer 
5'- TCCCTTCCCATCCAGAGAAC-3' and the reverse primer 5'- GCAGAGGAGATGTTTGCTGA-3' 
designed in this study using Primer BLAST and OligoAnalyzer. PCR reagent concentrations 
and cycling conditions as per Supplementary Table 6.1 and Supplementary Table 6.2. This 
region contains the SNPs rs6588807, rs144935309, rs147969184, rs141937160, 
rs145804175, rs145494220, and rs28675287 previously associated with ASD (Holt et al. 
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2010; Wang et al. 2013). The success of the PCR, and the PCR product size, was confirmed 
by electrophoresing the PCR product on a 1.2 % (w/v) agarose gel in 1 X TAE buffer stained 
with ethidium bromide.  
2.5 SEQUENCING 
Sequencing of the two genomic PCR fragments of ASMT was completed by the Centre for 
Analytical Services (CAF) at the University of Stellenbosch, South Africa. CAF used the BigDye 
Terminator V3.1 sequencing kit (Applied Biosystems) in an Applied Biosystems 3730xl DNA 
Analyzer, using the manufacturers protocol with slight modifications. CAF performed data 
collection and sequence analysis using the Applied Biosystems DATA Collection v3.0 and 
Applied Biosystems Sequence Analysis v5.3. 
2.6 SINGLE NUCLEOTIDE POLYMORPHISM GENOTYPING 
The resultant sequences were edited and aligned using Chromas v2.4 (Technelysium Pty Ltd) 
and Mega 6.06 (Build no.: 6140226). The sequences were aligned with the Homo sapiens 
chromosome X, GRCh38.p2 Primary Assembly (NCBI Reference Sequence: NC_000023.11) 
Add download date from NCBI Nucleotide. The forward and reverse sequences for each 
individual overlapped, therefore SNPs were only confirmed if they were present in both 
reads. 
2.7 STATISTICAL ANALYSIS 
Statistical analysis on both the genotype and allele quantitative data was performed using 
RStudio (Version 0.99.489 – © 2009-2015 RStudio, Inc.). Given the sample sizes, a two-tailed 
Fisher’s Exact test was used to compare subsets of the data grouped based on phenotype 
(using the fisher.test function in RStudio). Hardy-Weinberg exact tests (GenePop, web 
version 4.2, http://genepop.curtin.edu.au/genepop_op1.html) were used to test for Hardy-
Weinberg equilibrium. Haplotyping of the genetic data was done using Haploview (Barrett 
et al. 2005). SNP functional implications were assessed using Ensembl Variant Effect 




2.8 PHENOTYPIC GROUPING 
The first line of comparison was to compare the entire ASD cohort based on the ADOS 
module with which they were assessed. Given that the choice of ADOS module is selected 
based on the verbal fluency of the child, the module number was used as a proxy for 
language development. Module 1 is used for participants with no language/limited single 
word usage, Module 2 for simple phrase speech and Module 3 for fluent speech. The second 
comparison used on the entire cohort was based on ancestry, to establish whether there is 
differential SNP frequency based on population stratification. However, this is a poor 
approximation of the whole South African population, as discussed later. Comparisons 
between sub-phenotypes within the ASD cohort and the controls were based on the ADOS 
Classification and Symptom Severity. ADOS Classification falls into three categories (Autism, 
Autism Spectrum, and Non-Spectrum), and Symptom Severity falls into four categories 




3.1 CHARACTERISTICS OF PARTICIPANTS IN THE STUDY COHORT 
A total of 50 children with a prior ASD diagnosis were screened using the ADOS-2 
assessment to obtain a research cohort of 32 children with ASD and seven children as 
controls. All study participants were male, aged 5 to 14 years old. Genomic DNA was 
sequenced for target regions in ASMT and genotyping of both gene regions was successful 
for n=36 individuals, with the remaining three individuals being genotyped for only one of 
the two gene regions. However, for the sake of a “clean” phenotype, all individuals with 
medical comorbidities were excluded from the final study sample (Table 2.1). One individual 
was excluded from the control group based on their ADOS score being above the agreed 
cut-off of a total ADOS score over zero. This stringent cut-off was selected to ensure a clean 
phenotype of true control typically developing candidates. Thus the final study sample 
consisted of 28 ASD cases and six controls, with a total of 32 individual sequences for both 
target regions, and two partial sequences.  
Within a South African context, ethnicity is difficult to establish, as the general population is 
made up of multiple nationalities and heritages. Thus participants were divided into three 
broad groups based on self-reported ancestry: Black Ancestry (BA), Mixed Ancestry (MA), 
and White Ancestry (WA) (Table 3.1). The BA group was underrepresented in both the ASD 
and typically developing control cohorts, predominantly due to the demographic range in 
the two schools. This is partly a result of the fact that administrators for this study are 
English speakers and had been accredited to administer the assessment in English only. A 
further limitation is that the typically developing control group comprised entirely of 
individuals of WA. Hardy-Weinberg testing of both ASD and control groups showed that 
both populations were in Hardy-Weinberg equilibrium for all loci (Supplementary Table 6.7 





Within the final study sample, the following ADOS Symptom Severity scores were observed:  
High, n=5, Moderate, n= 20 and Low, n= 3. The six individuals in the control group were 
categorised as having Minimal/No Evidence of ASD symptoms.Participants were screened 
using an ADOS module appropriate for their spontaneous, expressive language. This study 
used Modules 1 to 3 for assessment of participants because of the restricted age range 
used; the oldest participants were two 14 year old boys with ASD who were both pre-verbal. 
Module 1 and 2 were used for the majority of the ASD participants, and Module 3 was used 
for all controls as well as four ASD participants (see Table 3.1). For a detailed breakdown of 
all participants’ demographic data, see Supplementary Table 6.3. 
Table 3.1 Table indicating the selection criteria for the endophenotypes used in this study, as well as 
the demographic breakdown of each endophenotype, and the number of participants in each 
subgroup. Symptom Severity is based on the overall ADOS score of a participant, their age, and the 
Module with which they were assessed. The ADOS Module choice is based on the verbal fluency of a 
participant: Module 1 is used for children with no speech or limited, single words; Module 2 is used 
for children who use simple, meaningful phrase speech; and Module 3 is used for children with 
verbal fluency 
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3.3 PUTATIVE SINGLE NUCLEOTIDE POLYMORPHISMS ASSOCIATED WITH AUTISM 
The SNPs identified in this study are indicated in Table 3.2. This study identified two novel 
SNPs: IVS4-225C>A and IVS5+124G>T. Table 3.3 indicates the population allele frequencies 
for the SNPs from the 1000 Genomes Project, where this data is available, in addition to the 
allele frequencies for these SNPs in the three broad population groups in this current study. 
The SNP allele and genotypic counts were tested for significance by comparing the different 
endophenotypes using Fisher’s Exact Test for count data. Table 3.4 shows the pairwise 
comparisons that are significant (p-value <0.05), as well as comparisons with p-values of 
between 0.05 and 0.1. While the comparisons are statistically underpowered, the higher p-
values are included for consideration, as they may indicate a trend towards significance. For 
this study, correction for multiple testing was not used due to the small sample size. 
Using the ADOS module to differentiate between ASD phenotypes, SNP rs148520524 
differed in frequency in the Module 1 versus Module 2 comparison of the ASD study 
participants. These participants were between five and fourteen years of age at the time of 
assessment, and had severely limited verbal development in relation to their chronological 
age expectations. The SNP rs6588807 differed in frequency between ASD endophenotypes 
with High ADOS Symptom Severity Scores compared to ASD participants with Moderate 
ADOS Symptom Severity Scores. There were three other notable SNPs, of which rs5989681 
and rs56690322 significantly differ in frequency between participants of Black Ancestry 
compared to participants of White or Mixed Ancestry. Both rs5989681 and rs56690322 have 
previously been associated with ASD (Melke et al. 2008). However, this association with 
ancestry should be treated with caution because the BA participants are clearly not well 
represented in the study sample (n=3). The overall small sample size, combined with a small 
control group of WA-only participants, further emphasises that the allele frequencies seen 
in this study may not be a true representation of the genetic variability in South Africa. The 
last SNP rs186757787 also occurred significantly more frequently in participants of BA than 




Table 3.2 Table indicating the genotype frequencies, and counts in brackets, of the control group 
and the ASD cohort. SNPs indicated with (*) have previously been associated with ASD in the 
















































CC 100 (6) 75 (3) 90 (18) 66 (2) 
GA - 20 (1) 25 (5) - CT - - 10 (2) 33 (1) 
























TT 100 (6) 100 (4) 100 (20) 100 (3) 
TC - - 15 (3) - CT * - - - 






















GG 100 (6) 100 (4) 95 (19) 100 (3) 
GC 20 (1) 40 (2) 55 (11) 66 (2) GA - - 5 (1) - 
























TT 83 (5) 100 (4) 70 (14) 66 (2) 
GA 20 (1) 40 (2) 30 (6) 33 (1) CT 17 (1) - 30 (6) 33 (1) 






















GG 100 (6) 100 (4) 95 (19) 100 (3) 
TC 60 (3) 40 (2) 60 (12) 66 (2) GA - - 5 (1) - 





















GG 83 (5) 100 (4) 100 (20) 100 (3) 
GC - - 5 (1) - GT 17 (1) - - - 





















GG 100 (6) 100 (4) 100 (20) 66 (2) 
AC - - 5 (1) - GA - - - 33 (1) 









 AA 50 (3) 25 (1) 20 (4) 33 (1) 
 
     
AC 50 (3) 50 (2) 70 (14) 33 (1)      
CC - 25 (1) 10 (2) 33 (1)      
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Table 3.3 Allele frequencies in the five super population groups, from the 1000 Genomes Project 
(Batch ID: Phase 3_V1), and the three population groups from this current study. The sample size for 
each population is indicated in brackets as the number of alleles per group (i.e. 2n). The top allele is 
the major allele for that population, and the bottom allele is the minor allele. 































































































































































































BA= Black Ancestry, MA= Mixed Ancestry, WA= White Ancestry 
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Table 3.4 SNPs found to differ in frequency between endophenotypes within the ASD cohort and 
controls. Significance is set at p<0.05, but p-values <0.1 are also shown. (1) indicates 
endophenotypes where the genetic data for cases and controls was pooled, (*) indicates SNPs that 
have been linked to ASD in previous studies (Melke et al. 2008; Veatch, Pendergast, et al. 2015) 
 
3.4 HAPLOTYPES 
The Final Study Sample, consisting of all individuals in the dataset that are free of 
comorbidities, was examined for linkage disequilibrium between any of the SNPs found in 
this study. SNPs rs5989681, rs56690322 (P1BC) and rs6644635 are in linkage disequilibrium, 
which partially corresponds to the ‘risk’ haplotype identified by Melke et al (2008). Melke et 
al (2008) found the haplotype GGGC of SNPs rs4446909, rs5989681, rs56690322 (P1BC) and 
rs6644635 to be significantly associated with ASD. However, in this study, rs4446909 does 
not seem to be in significant linkage disequilibrium with rs5989681, rs56690322 (P1BC) and 
rs6644635 (see Figure 3.1a). The SNP rs186757787, however, displays linkage disequilibrium 
with rs5989681, despite its location 14kb away from the promoter region (Figure 3.1a). Of 
these SNPs, all but rs6588807 are significantly associated with ancestry (Table 3.4). These 
four SNPs are indicated in the figure by a haplotype block.  
When comparing the count data of rs5989681 (G>C), rs56690322 (G>A), rs6644635 (C>T), 
and rs186757787 (C>T) together (see Table 3.5) using Fisher’s Exact Test, the haplotype 
GGCC is more frequent (p-value of 0.0566) in the controls than in the ASD cohort. It is worth 
noting that the minor alleles of these SNPs do not occur significantly more frequently 
individually in the ASD cohort than in the controls (Supplementary Figure 6.4). It can also be 
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in the MA (p-value=0.0123) or the WA (p-value=0.0102) groups. Likewise, rs56690322 is 
significantly more common in the BA group than in the MA (p-value=0.0207) or WA (p-
value=0.0028) groups. As stated before, the ancestry data should be treated with caution, 
however, due to our sample size that is not representative of the whole South African 
population. 
Table 3.5 Table indicating the haplotype counts in the ASD group vs. the controls, along with the p-
values derived using Fisher’s Exact test. Significance is set at p<0.05. The SNPs are rs5989681 (G>C), 
rs56690322 (G>A), rs6644635 (C>T), and rs186757787 (C>T) 
Haplotype ASD % (n=27) Controls % (n=5) p-value 
CACC 11.1 (3) - 0.5897 
CACT 3.7 (1) - 0.8438 
CGCC 37.0 (10) 20 (1) 0.4280 
CGCT 11.1 (3) - 0.5897 
GACC 14.8 (4) 20 (1) 0.5991 
GATC 3.7 (1) - 0.8438 
GGCC 14.8 (4) 60 (3) 0.0566 
GGTC 3.7 (1) - 0.8438 
ASD= Autism Spectrum Disorder participants 
 
In an attempt to eliminate the possibility of ancestry being a confounding factor, a linkage 
disequilibrium map was generated with only WA and MA participants from the Final Sample 
set. The ideal would be to test for LD for each ancestry group individually, but the small 
sample size negatively impacts the power of the comparison. The results indicated that only 
rs56699322 and rs4446909 were in linkage disequilibrium, with insufficient data for the 
remaining loci (see Figure 3.1b). There was no significant association between the haplotype 




Figure 3.1 Linkage disequilibrium maps generated in Haploview using the genotypic data from participants in the ASD cohort, and the controls. Blue blocks 
indicate insufficient information for that locus, with the numbered blocks indicating weak linkage disequilibrium, and the red blocks indicating loci that are 
in strong linkage disequilibrium (Barrett et al. 2005). (a) Haplotype structure of ASMT promoter region and target intron/exon boundary, based on genotype 
data from the final research cohort (Table 2.1). The black haploblock indicated was inserted manually, to indicate the four SNPs that exhibit some LD with 





The ASD ‘risk’ haplotype frequency, as proposed by Melke et al (2008), was also investigated 
(Table 3.6). The GGGC haplotype was present significantly more frequently (p-value= 0.313) 
in the Control group than in the ASD group. This relationship held true (Supplementary 
Table 6.5) regardless of whether entire final sample (n= 34) was used, or whether the BA 
participants were excluded (n= 31). 
Table 3.6 Table indicating the haplotype counts in the ASD group vs. the controls, for the ‘risk’ 
haplotype first identified by Melke et al (2008). The p-values derived using Fisher’s Exact test. 
Significance is set at p<0.05. The SNPs are rs4446909 (G>A), rs5989681 (G>C), rs56690322 (G>A), 
rs6644635 (T>C). 
Haplotype ASD % (n=27) Controls % (n=5) p-value 
ACAC 7.1 (2) - 0.7159 
GCAC 7.1 (2) - 0.7159 
GGAC 14.3 (4) 20 (1) 0.5859 
ACGC 14.3 (4) - 0.5004 
GCGC 32.1 (9) 20 (1) 0.5149 
AGGC 3.6 (1) - 0.8485 
GGGC 10.7 (3) 60 (3) 0.0313 
GGAT 7.1 (2) - 0.7159 
GGGT 3.6 (1) - 0.8485 
ASD= Autism Spectrum Disorder participants 
 
3.5 DELETERIOUS SINGLE NUCLEOTIDE POLYMORPHISMS 
For the majority of the SNPs observed in this study, the effect of alleles on gene expression 
has not been characterised, if indeed the polymorphisms have any effect. This is particularly 
the case for the SNPs in the intronic region, where there is no prior information on the 
contribution of either allele to gene function or expression. Indeed, in silico software (e.g. 
SIFT and Ensembl Variant Effect Predictor) were unable to predict the effects of these 
intronic SNPs. However, a missense SNP and a splice donor variant were identified (Table 
3.7) in addition to three SNPs in the promoter region. The SNPs, their potential effects and 
frequencies are summarised in Table 3.7. Analysis using Alibaba identified putative 
transcription factor binding sites in both regions. 
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Table 3.7 The position and functional implication of non-synonymous SNPs identified in this cohort. 
Frequency of SNPs is indicated per endophenotype. SNPs present in individuals who were excluded 
from the final sample are reported as “Unknown Developmental Deficit”. Exclusion was due to 
presenting ASD with comorbidity, or presenting some undiagnosed developmental deficit without 
ASD. Functional implication were predicted using dbSNP and Ensembl Variant Effect Predictor on 
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ASD= Autism Spectrum Disorders; UDD= Unknown Developmental Deficit. 
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The SNPs, rs4446909, rs148520524, and rs5989681 are predicted to be within the 
transcription factor (TF) binding sites of the promoter region of ASMT (Figure3.2) (Jonsson 
et al. 2010). Analysis using Alibaba identified two additional SNPs, rs56690322 and 
rs6644635, which are within putative TF binding sites. 
 
 
 Figure 3.2 Sequence and putative transcription factor binding sites in the ASMT gene promoter 
region spanning X: 1614846-1615299. The primer sequences are indicated in dark grey. The SNPs 
found in this study are indicated in dark pink, with the binding sites in light grey. CCAC boxes and 
CAAT-BOX are indicated in yellow and green respectively. Binding sites were identified using Poly-
Phen and SIFT analysis by Jonsson et al (2010). The design and layout of this image is taken from 
Jonsson et al 2010, and edited to include the primers and SNPs from this study. 
 
 
The missense SNP, rs774990880, in within exon 1 of ASMT, which is included in three 
protein coding transcripts of ASMT (Ensembl transcript IDs: ENST00000381241, 
ENST00000381233, ENST00000381229). The clinical significance of this amino acid change is 
unknown. This SNP was found in the genome of VG15 only (see Supplementary Table 6.3) 
who is a 14-year old pre-verbal male with ASD of WA. This participant was assessed using 
ADOS Module 1, and scored as “Autism” with Moderate Symptom Severity. 
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In the region spanning X: 1629573-1630120, the SNPs rs6588807, rs184583293 and 
rs28675287 occur in putative TF binding sites (Table 3.7, Figure 3.3), and rs148855515 
occurs in a splice donor region. Two of the TF binding site SNPs occurred in only one 
individual each: rs184583293 in CP14, a 7-year old male of MA, who scored as Autism 
Moderate on ADOS Module 2; and rs776976390 in CP05, a 6-year old male of MA, who 
scored as ASD Low on ADOS Module 1. Their respective ages at the time of assessment, and 
the ADOS Modules with which they were assessed, indicates that CP14 has phrase speech, 
and that CP05 is pre-verbal. 
 
 
Figure 3.3 Sequence and putative transcription factor binding sites of the section of the ASMT gene 
intronic region spanning X: 1629573-1630120. The primer sequences are indicated in dark grey The 
SNPs found in this study are indicated in dark pink, with the putative binding sites in light grey. 
Binding sites were identified using Alibaba 
 
The splice donor variant, rs148855515 (Table 3.7), occurs in intron 5 of ASMT, two bases 
from the end of exon 5 (see Figure 3.3). This SNP location corresponds to Hg18 build 
IVS5+2T>C, which was previously found to be associated with ASD, and ASD with severe 
intellectual impairment (Pagan et al. 2011). This splice site polymorphism disrupts ASMT 
activity, which in turn affects melatonin synthesis, as shown in cell culture as well as in vivo 
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(Melke et al. 2008). This SNP was present in the genome of only one participant, CP15, who 
was excluded from the final study sample due to undiagnosed developmental limitations. 
This participant is a male of WA, and was 9 years old at the time of assessment. He was 
assessed using ADOS Module 3, and scored as “Non-spectrum”. 
 
Table 3.8 Table indicating the participant data for SNPs found to be associated with a particular 
endophenotype. SNPs indicated with (*) have been associated with ASD previously. (1) indicates TF 
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4.1 VERBAL FLUENCY AND AUTISM SPECTRUM DISORDERS 
Before starting an ADOS assessment, one of the first decisions that the research assessors 
make, is which ADOS module is most applicable to the verbal fluency and age of the 
participant, as previously discussed (Table 1.1). Module 1 is used for individuals who are 
“pre-verbal”, with fewer than five words, or for individuals unable to use spontaneous, 
meaningful phrases. Module 1 is generally intended for younger children, but can be 
adapted for use in older children or adults who do not have phrase speech or fluent 
language. Module 2 is intended for individuals with phrase speech; which is defined as using 
more than three words with simple grammatical markings. Module 3 is aimed at individuals 
who speak with verbal fluency, and this module was completed by all our control 
participants (five to ten years old). Here language is comprised of complex sentences are 
used in a mostly grammatically correct manner, with some complex sentences using clauses. 
Module 4 is used for adolescents and or adults for whom an interview assessment is more 
appropriate than a play-style interview (Lord et al. 1989). 
Using the developmental marker of spontaneous, expressive language with respect the 
different ADOS module used, a significant association was found with ASD and SNPs in the 
promoter region of ASMT. In the Module 1 vs. Module 2 comparison, rs148520524 is only 
present in ASD participants assessed with Module 2 (p=0.0711). DSM-5 and ADOS-2 do not 
require delays in expressive language development as a criterion for an ASD diagnosis, 
because language acquisition in ASD is so variable. In fact, individuals who are completely 
verbally fluent (Module 3) can still have debilitating impairments in social communication or 
pragmatic language. However, the Module 1 vs. Module 2 differences observed in this study 
hint at a real ASD endophenotype. It has been reported that individuals with ASD who are 
pre-verbal (Module 1) tend to experience greater symptom severity, often with 
accompanying intellectual impairment (Luyster et al. 2008). 
The SNP rs148520524 falls within a putative AP-1 transcription factor (TF) binding site 
(Figure 3.2) in the promoter region of ASMT (Jonsson et al. 2010). AP-1 TFs regulate gene 
expression in response to a variety of stimuli, such as cytokines or growth factors (Angel & 
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Michael Karin 1991). AP-1 is involved in a variety of cellular processes, such as apoptosis and 
cell differentiation (Ameyar et al. 2003). These TFs usually form a complex with other 
subunits in order to bind to palindromic 5’-TGAG/CTCA-3’ sequences, which means that the 
rs148520524 C>T substitution may disrupt AP-1 binding (Angel et al. 1987). However, 
specificity of the AP-1 complex may vary depending on dimer composition (Angel & Michael 
Karin 1991), so the SNP may not have an appreciable effect on ASMT transcription.  
If this SNP does have a large enough effect on ASMT transcription to impact melatonin 
biosynthesis, the contribution this polymorphism would have to the development of 
language deficits is not immediately apparent. Decreased expression of A-ANAT (Hu et al. 
2009; Hu & Steinberg 2009), and low melatonin levels (Tordjman et al. 2013), have (in some 
cases) been found to be associated with severe language delays in ASD. Despite this 
putative association, no direct mechanism by which melatonin could influence language has 
not been characterised. However, potential causes have been suggested.  
Firstly, melatonin has been linked to neural development and calcium signalling (De Faria 
Poloni et al. 2011). Extra-pineal melatonin is synthesised in mammalian placental tissue 
during the first trimester of pregnancy, and melatonin receptor gene expression is higher in 
embryos than in adults (Iwasaki et al. 2005; Von Gall et al. 2002). It is thought that it plays a 
role in embryonic neurodevelopment through melatonin regulating the calcium signalling 
system, in turn modulating intercellular signalling cascades (Iwasaki et al. 2005) 
Secondly, sleep disruption has been linked to language delays in children with 
developmental disorders (Giannotti et al. 2008; Axelsson et al. 2013). Melatonin deficiency 
has been associated with disrupted sleep (Kawabe et al. 2014). The deleterious effects of 
sleep disruption in general has been well-documented in typically developing adults 
(Samkoff & Jacques 1991), as well as the effect of sleep disruption on the behaviour of 
typically developing children (Sadeh 2007). These negative health outcomes are 
compounded in children with developmental disorders, where sleep disruption may form 
part of the genetic aetiology of their disorders. The effects of sleep disruption may 
contribute to existing behavioural and cognitive impairments (Axelsson et al. 2013). 
The possible association between rs148520524 (p=0.0711) and the phrase-speech 
endophenotype suggests that ASMT could possibly have a role in structural and pragmatic 
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language impairments. However, ASD language phenotypes are complex, and have been 
associated with multiple polymorphisms in the genome (Bradford et al. 2001; Chen et al. 
2006; Alarcón et al. 2005). The language phenotype needs to be more clearly defined and 
stratified before strong claims can be made about possible associations between ASMT and 
language delay in ASD. In addition, it has been noted that the contactin-associated protein-
like 2 gene has been implicated specific language impairment (SLI), as well as an ASD 
(Grzadzinski et al. 2013). Therefore it is important to have an independent test of language 
ability in addition to the ADOS-2 assessment. This would allow the discrimination of 
whether the difference in SNP frequency observed between Module 1 and Module 2 is due 
to a SLI, an ASD endophenotype or another associated factor.  
When considering language endophenotypes, it is necessary to consider factors such as 
cognitive impairment. Cognitive impairment is more common among individuals with ASD 
who meet the criteria for a Module 1 ADOS assessment, and it could influence language 
development (Luyster et al. 2008). There are many language assessment tools (e.g. Peabody 
Vocabulary Test), which could confirm impairment in spoken language. However, most tools 
have some limitations. These limitations are the potential for cultural biases in South Africa 
(Haitana et al. 2010; Rock & Stenner 2005), and lack of applicability across the autism 
spectrum (e.g. Raven’s Progressive Matrices only used for pre-verbal participants). 
A further factor to consider, particularly in the South African context, is that it is a multi-
lingual country, with most people speaking at least two languages. In this study the ADOS 
was administered in English, the schools that were approached for this study use English as 
the language of instruction, and three of the participants in this study did not use English as 
their home language. Noteworthy is that all three of these boys were preverbal and 
completed a Module 1 ADOS assessment. There has been a debate about the application of 
any diagnostic tool in a variety of languages, particularly tools designed to assess verbal 
interaction, and whether it may negate the standardisation. Non-Western cultural norms 
may also interfere with tests that were developed for Western children. An example of this 
bias is as found by Rock & Stenner (2005) when reviewing school readiness tests. These 
additions will follow as this cohort is grown, as ADOS has not been widely used in assessing 
ASD in South Africa. This the first study of its kind in South Africa, and the significance of 
studying a South African population is the genetic diversity as well as the cultural diversity. 
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Therein lays the need to validate tools that have been developed for use in other contexts. 
As the cohort grows, potential bias this will be easier to evaluate. 
The SNP rs6588807 was found to be tentatively associated (p-value= 0.06812) with ADOS 
Symptom Severity, occurring more frequently in the participants with “Moderate” than 
“High” Symptom Severity. The putative CEBPG site containing this SNP does not give a clear 
indication of its functional significance, as this TF has been linked to bronchial carcinoma, 
but no other clinical or psychiatric conditions. It could conceivably form part of a 
downstream enhancer complex for ASMT, as CEBPG TFs do act as enhancers, but there is no 
published evidence of an enhancer region in ASMT introns. The SNP was identified in and 
ASD study on European subjects, but no statistical significance was found (Holt et al. 2010). 
In addition to potential cultural and linguistic effects, the unique ancestral heritage of the 
South African population may act as a confounding factor in ASD genotyping. Two SNPs, 
rs5989681 and rs186757787 occurred significantly more frequently in the BA group than in 
the MA (p-values of 0.0123 and 0.0207 respectively) or the WA (p-values of 0.0102 and 
0.0028 respectively) groups (Table 3.8). As the BA group is clearly underrepresented in the 
study sample (n=3), it is possible that this may be due to the limited sample size. However, 
data from the 1000 Genomes Project indicates that the allele frequency for rs5989681 is 
different in the African super population than in the other four super populations (Table 
3.3). In the Admixed American, South and East Asian, and European populations the G allele 
is the major allele, but in the African super population the C allele is the major allele. By 
inspection of Table 3.3 it is visible that the disparity in frequency if the G versus the C allele 
is greater in our BA group than in the African super population, but it is reasonable to 
assume that this is the product of our small sample size. The minor (T) allele frequency for 
rs186757787 is greater in the African super population than in the Admixed American super 
population, and is absent from the other three super populations (Table 3.3). In our three 
ancestry groups, the T allele appears most frequently in the BA group, appears at a lower 
frequency in the MA group, and is absent from the WA group. While these observations hint 
at demographic effects in our study, it would be necessary to increase the number of BA 
participants in the study, as well as increasing the sample size overall, to establish if this 
association is due to sample size, or population demography. 
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The functional effect of rs186757787 is unknown, as it falls in the intronic region, and none 
of the software used in this study found any putative TF binding sites at this position (Figure 
3.3). The SNP rs5989681, on the other hand, has been associated with ASD endophenotypes 
in previous studies, and falls in a nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-κB) binding site (Jonsson et al. 2010). Previous studies have suggested that NF-κB 
TFs play a role in synaptic plasticity and memory, which have in turn been linked to language 
development (Mattson & Camandola 2001; Romano et al. 2006; Kalkman 2012; Hu et al. 
2009). Melke et al. (2008) found the G allele of rs5989681 to appear more frequently in 
ASD, and to be associated with decreased expression of ASMT transcript (P= 2 x 10-10). 
The last SNP approaching a significant difference in frequency was rs56690322 (p-value= 
0.0440), between participants of MA (n=15) and WA (n=16). These two groups are better 
represented in the study cohort, which makes the comparison more meaningful than the 
comparisons between the BA group and the WA or MA group. This SNP has been identified 
in previous ASD studies (Melke et al. 2008; Pereira et al. 2013; Wang et al. 2013), and forms 
part of the Melke et al. GGGC “risk” haplotype. However, this study found no significant 
difference in the minor (A) allele frequency when comparing ASD endophenotypes to 
controls. This minor allele appeared more frequently in the MA ancestry group, suggesting 
that it may be a more variable region in certain ancestry groups, without contributing to a 
disease state. The allele frequencies for this SNP from the 1000 Genomes Project (Table 
3.3), do suggest that the minor allele occurs at a low frequency in all five of the super 
populations. If this SNP did contribute to the ASD phenotype, a possible mode of action for 
this would be through its location in a putative SRF TF binding site. A knockout mouse study 
found that if this family of TFs is not expressed in the hippocampus, it negatively impacts the 
neurological process of long-term depression (Etkin et al. 2006). Long-term depression (LTD) 
is a process that weakens synaptic affinity in response to a stimulus, which contributes to 
the process of memory formation and learning (Massey & Bashir 2007). SRF TFs perform 
several functions in different tissues, which also includes neuronal embryonic development 
in humans (Cooper et al. 2009). It is possible that this SNP does not contribute to the ASD 
phenotype on its own, but rather as part of a haplotype. 
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4.2 AUTISM RISK HAPLOTYPES 
While several polymorphisms in ASMT have previously been found in ASD patients, there 
has not been consensus on which SNPs, if any, contribute directly to ASD aetiology (Veatch, 
Goldman, et al. 2015). The finding of a “risk” haplotype identified by Melke et al (2008) has 
not been reproduced in subsequent studies (Wang et al. 2013; Veatch, Pendergast, et al. 
2015). Indeed, in this study, the GGGC haplotype was found to be significantly associated 
(p=0.0313) with the typically-developing Control group (Table 3.6). As the data from this 
study hints at ancestry effects (Table 3.4, Figure 3.1b), this comparison was repeated with 
WA and MA participants only. Unfortunately, attempting the LD comparison using the WA 
or MA groups individually resulted in a map without enough statistical power to indicate LD 
at all. However, regardless of whether entire final sample (n= 34) was used, or whether the 
BA participants were excluded (n= 31), the GGGC haplotype was still significantly associated 
with the Control group (Supplementary Table 5.7). Furthermore, the ACGC haplotype, which 
Melke et al (2008) found to be significantly associated with their Control group, showed no 
significant association (p=0.5004) with either the ASD group or the Control group. 
When testing for linkage disequilibrium among the SNPs found in this study (Figure 3.1a), 
three of the SNPs from the Melke (2008) ‘risk’ haplotype are in linkage disequilibrium 
(rs5989681, rs56690322, and rs6644635). Additionally, the SNP rs186757787 forms part of 
this haplotype, despite its position 14kb downstream from the ‘risk’ haplotype SNPs. These 
four SNPs are indicated by a black haploblock, inserted manually for clarity (Figure 3.1a). 
Three of these SNPs (rs5989681, rs56690322, and rs186957787) are associated with 
ancestry in this study (Table 3.4), with the remaining SNP (rs6644635) showing no significant 
association with any of the endophenotypes in this study. As can be seen in Table 3.5, the 
GGCC haplotype shows strong association with the Control group. This haplotype 
constitutes the major alleles for rs5989681, rs56690322, s186757787, rs6644635 (Table 
3.2).  
Due to the strong association between three of the SNPs in this haplotype and ancestry, the 
LD analysis was repeated using only the MA and WA participants from the final sample set 
(Figure 3.1b). Based on the genotypes of the MA and WA participants, only rs56690322 and 
rs6644635 are in LD. None of the possible haplotypes of these two SNPs are significantly 
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associated with either the ASD or Control group. Though not all of the SNPs are in significant 
LD, the GGCC haplotype indicated in Figure 3.1a is still strongly associated with the Control 
group (Supplementary Table 6.6). 
4.3 CONCLUSION AND FUTURE RESEARCH 
Based on the results of this study, the “risk” haplotype identified by Melke et al (2008) 
appears to not be implicated in the aetiology of endophenotypes in South African 
individuals with ASD. The homozygous presence of the major alleles of rs4446909 and 
rs5989681 is strongly associated with the Control group in this study, in contrast to what 
was found by Melke et al (2008). Thus this study found no association between this 
haplotype and ASD risk, similar to previous studies (Toma et al. 2007; Wang et al. 2013). 
However, the small sample size of this study necessitates that this finding be treated with 
caution. It is not known whether the GGGC “risk” haplotype that these authors found to be 
associated with decreased ASMT expression, and by extension decreased melatonin levels, 
will have the same effect in this South African population. Instead, this study has found 
some evidence of possible rare variants in BA individuals with ASD, though further studies 
on much larger sample sizes would be required before this evidence can be considered 
conclusive. Larger sample sizes would also allow for corrections for multiple testing, such as 
the Bonferroni Correction, or the Holm-Bonferroni Method. 
This study also identified a SNP not previously associated with ASD, rs148520524, which is 
associated with individuals with ASD who were tested using ADOS Module 2 (phrase 
speech), and not in individuals tested with ADOS Module 1 (pre-verbal). This SNP falls in an 
AP-1 TF binding site (Figure 3.2), which could have an effect on neural development, as 
previously discussed. This association could potentially be elucidated using language testing 
tools in addition to the ADOS-2 to establish whether it is due to an ASD endophenotype, or 
an independent language impairment. Further endophenotyping could also aid in 
establishing the association between the SNP rs6588807 and ADOS Symptom Severity. 
As part of the central premise of the putative role of ASMT in ASD is melatonin synthesis, 
quantitative testing of blood melatonin levels (or melatonin metabolites in urine) would be 
required to confirm the association. To confirm whether melatonin or melatonin metabolite 
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levels are associated with sleep disruption in ASD, sleep diaries and actigraphy data would 
give an indication of the circadian cycles of the ASD cohort. Additionally, expanding the 
genetic screening of participants to include other genes involved in the melatonin pathway 
could better characterise the contribution of melatonin to ASD aetiology. These genes could 
include the genes for melatonin receptors (MT1 and MT2), the rate limiting enzyme in 
melatonin biosynthesis (A-ANAT), and the gene for the enzyme responsible for metabolising 
melatonin (CYP1A2). If little to no variation in these genes is found to be associated with 
ASD, it would imply possible dysfunction in the central oscillator. If it is established that 
melatonin deficiency (as a result of a polymorphism) results in sleep disruption in individuals 
with ASD, and that these same individuals have impairments in language development, it 
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6 SUPPLEMENTARY MATERIALS 
 
Supplementary Figure 6.1 Sample of consent form used in this study 
 
 
Supplementary Table 6.1 Polymerase chain reaction (PCR) cycling conditions 















x35 0:20 58 0:20 56 
0:14 72 0:17 72 





Supplementary Table 6.2 Polymerase chain reaction (PCR) reagent concentrations using 
ThermoScientific Phusion High-Fidelity DNA Polymerase #F-530S 
Component 20µL reaction (µL) Final Concentration 
H2O 13.0 - 
5x Phusion GC Buffer* 4.0 1x 
10mM DNTPs 0.4 200 µM each 
Forward Primer 0.2 0.5 µM 
Reverse Primer 0.2 0.5 µM 
Template DNA 2.0 8ng per reaction 
Phusion DNA Polymerase 0.2 0.02 U/µL 
 *Kit comes with HiFi and GC buffer 
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Level of Symptoms Comorbidities Age 
Ethnic 
group 
CP01 3 3 Non-Spectrum Low Yes 7 WA 
CP03 3 6 Autism Moderate No 6 MA 
CP05 3 4 ASD Low No 8 WA 
CP07 1 7 Autism Moderate No 6 MA 
CP09 2 6 Autism Moderate No 6 WA 
CP12 3 6 Autism Moderate No 7 WA 
CP14 2 7 Autism Moderate No 7 MA 
CP15 3 2 Non-Spectrum Minimal/No evidence Yes 9 WA 
NT01 3 1 Non-Spectrum Minimal/No evidence No 7 WA 
NT02 3 1 Non-Spectrum Minimal/No evidence No 6 WA 
NT03 3 6 Autism Moderate Yes 7 WA 
NT04 3 1 Non-Spectrum Minimal/No evidence No 10 WA 
NT07 3 1 Non-Spectrum Minimal/No evidence No 6 WA 
NT10 3 1 Non-Spectrum Minimal/No evidence No 6 WA 
NT11 3 1 Non-Spectrum Minimal/No evidence No 7 WA 
VG01 2 7 Autism Moderate No 10 MA 
VG02 1 9 Autism High No 9 WA 
VG03 1 7 Autism Moderate No 8 MA 
VG05 1 8 Autism High No 6 WA 
VG06 2 6 Autism Moderate No 7 MA 
VG07 2 3 Non-Spectrum Low Yes 8 MA 
VG08 3 8 Autism High No 12 MA 
VG10 1 7 Autism Moderate No 6 MA 
VG11 1 6 Autism Moderate No 8 BA 
VG12 1 4 ASD Low No 6 MA 
VG13 1 4 ASD Low No 7 MA 
VG15 1 6 Autism Moderate No 14 WA 
VG16 1 6 Autism Moderate No 14 WA 
VG17 1 6 Autism Moderate No 8 WA 
VG18 1 10 Autism High No 8 MA 
VG19 1 9 Autism High No 8 BA 
VG20 1 6 Autism Moderate No 5 MA 
VG21 2 6 Autism Moderate No 10 WA 
VG23 3 6 Autism Moderate No 10 WA 
VG24 2 7 Autism Moderate No 9 BA 
VG26 2 6 Autism Moderate No 7 MA 
VG27 2 2 Non-Spectrum Low Yes 10 MA 
VG28 2 6 Autism Moderate No 10 MA 




Supplementary Table 6.4 P-values of Fisher’s Exact Tests comparing allele frequencies between endophenotypes 























rs4446909 0.5701 1 0.7085 0.336 0.6852 0.6731 1 1 0.3193 1 1 1 0.5829 
rs148520524 0.2945 0.3095 1 1 0.0711 1 0.2308 1 1 1 1 1 1 
rs5989681 0.0123 0.0102 1 0.09365 0.7417 0.5186 1 0.3034 0.2463 0.5588 0.7172 0.638 1 
rs56690322 0.3031 1 0.0440 0.6783 0.6852 1 1 1 1 0.5588 0.6527 1 0.6047 
rs6644635 0.3713 0.3854 0.8017 0.3377 0.7555 0.5344 0.5145 1 0.488 1 1 0.638 0.4402 
rs774990880 1 1 0.4839 1 1 1 1 1 1 1 1 1 1 
IVS4-225C>A 1 1 0.4839 1 1 1 1 1 1 1 1 1 1 
rs6588807 1 0.6582 0.6127 0.1025 0.5371 0.5434 1 0.3563 0.3184 0.3563 0.06812 1 1 
rs186757787 0.0207 0.0028 0.4923 0.5754 0.6133 0.2326 0.4762 0.1474 1 0.4 0.1241 1 0.4288 
rs148855515 1 1 1 1 1 1 1 1 1 1 1 1 1 
rs184583293 1 1 1 1 0.45 1 0.4762 1 1 1 1 1 1 
rs28675287 1 0.5348 1 1 0.6419 1 1 1 1 1 0.571 1 1 
rs191866206 1 1 1 1 1 1 1 1 1 1 1 1 1 
IVS5+124G>T 1 1 0.4839 0.1818 1 1 1 1 0.2308 1 1 1 1 
rs776976390 1 1 0.4839 1 1 1 1 1 1 0.4 1 1 0.1667 
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Supplementary Table 6.5 Table indicating the haplotype counts in the ASD group vs. the controls 
(WA and MA only), for the ‘risk’ haplotype first identified by Melke et al (2008). p-values derived 
using Fisher’s Exact test. Significance is set at p<0.05. The SNPs are rs4446909 (G>A), rs5989681 
(G>C), rs56690322 (G>A), rs6644635 (C>T). 
Haplotype p-value ASD % (n=25) Controls % (n=5) 
ACAC 0.6897 7.1 (2) - 
GCAC 0.6897 7.1 (2) - 
GGAC 0.6272 14.3 (4) 20 (1) 
ACGC 0.4616 14.3 (4) - 
GCGC 0.6711 32.1 (9) 20 (1) 
AGGC 0.8333 3.6 (1) - 
GGGC 0.0413 10.7 (3) 60 (3) 
GGAT 0.6897 7.1 (2) - 
GGGT 0.8333 3.6 (1) - 
ASD= Autism Spectrum Disorder participants 
 
Supplementary Table 6.6 Table indicating the haplotype counts in the ASD group vs. the controls 
WA and MA participants only, along with the p-values derived using Fisher’s Exact test. Significance 
is set at p<0.05. The SNPs are rs5989681 (G>C), rs56690322 (G>A), rs6644635 (C>T), and 
rs186757787 (C>T) 
Haplotype ASD % (n=24) Controls % (n=5) p-value 
CACC 12.5 (3) - 0.5539 
CACT 4.2 (1) - 0.8275 
CGCC 37.5 (9) 20 (1) 0.4243 
CGCT 4.2 (1) - 0.8275 
GACC 16.7 (4) 20 (1) 0.6421 
GATC 4.2 (1) - 0.8275 
GGCC 16.7 (4) 60 (3) 0.0747 
GGTC 4.2 (1) - 0.8275 





Supplementary Table 6.7 Table indicating the Hardy-Weinberg test output for the ASD group vs. the 
controls, with the p-values derived using Hardy-Weinberg Exact test. Significance is set at p<0.05. 
Test performed using GenePop web version 4.2 (http://genepop.curtin.edu.au/genepop_op1.html) 






 rs4446909 0.4373 0.0022 0.1429 0.1458 
 rs148520524 1 0 -0.0385 -0.0391 
 rs5989681 0.4276 0.0027 -0.1773 -0.18 
 rs56690322 1 0 -0.0425 -0.0432 
 rs6644635 0.7054 0.0017 -0.1309 -0.133 
 rs17149149 - - - - 
 IVS4-225C>A 1 0 -0.04 -0.0407 
 rs6588807 0.7107 0.0017 -0.0986 -0.1003 
 rs186757787 1 0 -0.04 -0.0407 
 rs148855515 - - - - 
 rs184583293 - - - - 
 rs28675287 1 0 -0.1304 -0.1326 
 rs191866206 - - - - 
 IVS5+124 G>T - - - - 







 rs4446909 - - - - 
 rs148520524 - - - - 
 rs5989681 - - - - 
 rs56690322 - - - - 
 rs6644635 1 0 -0.3333 -0.3571 
 rs17149149 - - - - 
 IVS4-225C>A - - - - 
 rs6588807 1 0 -0.25 -0.2667 
 rs186757787 - - - - 
 rs148855515 - - - - 
 rs184583293 - - - - 
 rs28675287 - - - - 
 rs191866206 - - - - 
 IVS5+124 G>T - - - - 
 rs77697639 - - - - 




Supplementary Table 6.8 Table indicating the Hardy-Weinberg test output for the entire cohort, 
with the p-values derived using Hardy-Weinberg Exact test. Significance is set at p<0.05. Test 
performed using GenePop web version 4.2 (http://genepop.curtin.edu.au/genepop_op1.html) 
Locus p-value S.E. 
Fis Estimates 
W&C R&H 
 rs4446909 0.3817 0.0023 0.1616 0.1645 
 rs148520524 1 0 -0.0323 -0.0327 
 rs5989681 0.68 0.0019 -0.1327 -0.1345 
 rs56690322 1 0 -0.0383 -0.0389 
 rs6644635 0.4864 0.0027 -0.1537 -0.1557 
 rs17149149 - - - - 
 IVS4-225C>A 1 0 -0.0323 -0.0327 
 rs6588807 0.7251 0.0017 -0.1013 -0.1027 
 rs186757787 1 0 -0.0323 -0.0327 
 rs148855515 - - - - 
 rs184583293 - - - - 
 rs28675287 1 0 -0.1228 -0.1245 
 rs191866206 - - - - 
 IVS5+124 G>T - - - - 
 rs77697639 - - - - 
 
 
